Association of Socioeconomic Health Care Disparities With Use of Anti-Vascular Endothelial Growth Factor and Visual Acuity Outcomes in Patients With Diabetic Macular Edema

BACKGROUND AND OBJECTIVE: This study characterizes the impact of race, ethnicity, insurance status, and geographic location on anti-vascular endothelial growth factor (VEGF) use for the treatment of diabetic macular edema (DME)

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 53(2022), 7 vom: 20. Juli, Seite 380-391
1. Verfasser: Greenlee, Tyler E (VerfasserIn)
Weitere Verfasser: Malhotra, Nisha A, Iyer, Amogh I, Conti, Thais F, Chen, Andrew X, Singh, Rishi P
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Angiogenesis Inhibitors Endothelial Growth Factors Ranibizumab ZL1R02VT79
LEADER 01000naa a22002652 4500
001 NLM34378288X
003 DE-627
005 20231226021241.0
007 cr uuu---uuuuu
008 231226s2022 xx |||||o 00| ||eng c
024 7 |a 10.3928/23258160-20220615-01  |2 doi 
028 5 2 |a pubmed24n1145.xml 
035 |a (DE-627)NLM34378288X 
035 |a (NLM)35858229 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Greenlee, Tyler E  |e verfasserin  |4 aut 
245 1 0 |a Association of Socioeconomic Health Care Disparities With Use of Anti-Vascular Endothelial Growth Factor and Visual Acuity Outcomes in Patients With Diabetic Macular Edema 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 22.07.2022 
500 |a Date Revised 10.08.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a BACKGROUND AND OBJECTIVE: This study characterizes the impact of race, ethnicity, insurance status, and geographic location on anti-vascular endothelial growth factor (VEGF) use for the treatment of diabetic macular edema (DME) 
520 |a PATIENTS AND METHODS: This study is a retrospective cohort study. The American Academy of Ophthalmology Intelligent Research in Sight Registry was queried for patients diagnosed with DME who received at least one anti-VEGF injection between 2012 and 2020 (n = 203,707). Multivariate regression analyses investigated associations between race, ethnicity, insurance status, and geographic location and anti-VEGF use and visual outcomes 
520 |a RESULTS: White race, non-Hispanic/Latino ethnicity, and private insurance were associated with higher use of anti-VEGF injections during a 60-month period (incidence rate ratio, 1.2, 1.25, and 1.17, respectively; P < .01). Furthermore, being of non-Hispanic/Latino ethnicity and having private health insurance were associated with higher longitudinal visual acuity (odds ratio, 1.44 [P = .02] and odds ratio, 1.43 [P < .01], respectively) 
520 |a CONCLUSION: Ethnicity and insurance status are associated with anti-VEGF use and visual acuity outcomes in DME. [Ophthalmic Surg Lasers Imaging Retina 2022; 53:380-391.] 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Angiogenesis Inhibitors  |2 NLM 
650 7 |a Endothelial Growth Factors  |2 NLM 
650 7 |a Ranibizumab  |2 NLM 
650 7 |a ZL1R02VT79  |2 NLM 
700 1 |a Malhotra, Nisha A  |e verfasserin  |4 aut 
700 1 |a Iyer, Amogh I  |e verfasserin  |4 aut 
700 1 |a Conti, Thais F  |e verfasserin  |4 aut 
700 1 |a Chen, Andrew X  |e verfasserin  |4 aut 
700 1 |a Singh, Rishi P  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Ophthalmic surgery, lasers & imaging retina  |d 2013  |g 53(2022), 7 vom: 20. Juli, Seite 380-391  |w (DE-627)NLM224956647  |x 2325-8179  |7 nnns 
773 1 8 |g volume:53  |g year:2022  |g number:7  |g day:20  |g month:07  |g pages:380-391 
856 4 0 |u http://dx.doi.org/10.3928/23258160-20220615-01  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_40 
912 |a GBV_ILN_63 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_90 
912 |a GBV_ILN_91 
912 |a GBV_ILN_130 
912 |a GBV_ILN_135 
912 |a GBV_ILN_136 
912 |a GBV_ILN_151 
912 |a GBV_ILN_181 
912 |a GBV_ILN_203 
912 |a GBV_ILN_217 
912 |a GBV_ILN_235 
912 |a GBV_ILN_289 
912 |a GBV_ILN_294 
912 |a GBV_ILN_297 
912 |a GBV_ILN_350 
912 |a GBV_ILN_352 
912 |a GBV_ILN_674 
912 |a GBV_ILN_676 
912 |a GBV_ILN_688 
912 |a GBV_ILN_698 
912 |a GBV_ILN_721 
912 |a GBV_ILN_737 
912 |a GBV_ILN_791 
912 |a GBV_ILN_812 
951 |a AR 
952 |d 53  |j 2022  |e 7  |b 20  |c 07  |h 380-391